Assembly of Alzheimer-like filaments from full-length tau protein  by Crowther, R.A. et al.
FEBS Letters 337 (1994) 135-138 LETTERS 
ELSEVIER 
FEBS 13510 
Assembly of Alzheimer-like filaments from full-length tau protein 
R.A. Crowther*, O.F. Olesen **, M.J. Smith, R. Jakes, M. Goedert 
Medical Research Council, Laboratory of Molecular Biology, Hills Road, Cambridge CB2 ZQH, UK 
Received 12 November 1993 
Abstract 
The principal fibrous component of neurofibrillary pathology in Alzheimer’s disease, the paired helical filament, is formed from hyper- 
phosphorylated microtubule-associated prot in tau. Here we show that recombinant tauprotein either in a non-phosphorylated stateor following 
phosphorylation with brain extract an be assembled in vitro into filaments resembling those seen in Alzheimer’s di ease. 
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1. Introduction 
Extensive neurofibrillary pathology, in the form 
of neurofibrillary tangles, neuritic elements in plaques 
and a network of neuropil threads in affected areas of 
the brain, is one of the defining characteristics of 
Alzheimer’s disease. Paired helical filaments (PHFs) 
form the principal abnormal fibrous component of such 
fibrillar deposits. Using preparations of PHFs from 
tangles it was shown that microtubule-associated tau 
protein forms a component of the PHF [l-3]. Bio- 
chemical analysis of preparations of dispersed PHFs 
produced by sarcosyl extraction [4] indicated that abnor- 
mally hyper-phosphorylated tau protein (known as 
PHF-tau or A68) is likely to be the sole component of 
the PHF [5]. 
In normal adult human brain six isoforms of tau pro- 
tein are produced by alternative mRNA splicing [6,7]. 
On gels PHF-tau runs as three retarded bands [4,5,8] but 
after extensive de-phosphorylation generates six bands, 
which align with the six recombinant isoforms [9], indi- 
cating that PHF-tau consists of all six isoforms in an 
hyper-phosphorylated state. Some of the sites of hyper- 
phosphorylation have been identified by using antibod- 
ies specific for the phosphorylated sites [5,10,11], others 
have been identified by direct sequencing [12]. Many of 
these sites can be phosphorylated in vitro by brain ex- 
tract [lO,ll] or by purified kinases [13-171. The isoforms 
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of tau protein contain towards the carboxyl-terminus 
three or four tandem repeats of 31 or 32 amino acids, 
which represent he microtubule binding domain of the 
protein [18,19]. The known phosphorylation sites, with 
the exception of Se?* [12,20], all lie in regions flanking 
the repeats. Proteolytic digestion of PHFs monitored by 
labelling with antibodies specific for various regions of
the protein indicates that the amino-terminal half of the 
protein and the carboxyl terminal form a fuzzy coat 
around the filament, while the repeat region forms the 
core of the structure [8,9,21]. Sequence analysis of tau 
fragments extracted from pronase treated tangle PHFs 
indicated that both three and four repeat isoforms con- 
tribute to the core but that in both cases a length corre- 
sponding to only three repeats is protected [22]. 
These observations uggested that it might be possible 
to produce PHF-like filaments in vitro using just the 
repeat region of tau protein, without the flanking regions 
and their attendant phosphorylation sites. Two different 
recombinant fragments of tau protein, each spanning 
approximately three repeats, produced filaments like 
Alzheimer PHFs [23,24]. To date it has not proved pos- 
sible to form PHFs in vivo in either transfected cell lines 
or transgenic animals. However, the ability to phospho- 
rylate recombinant au protein in vitro in a way similar 
to its abnormal phosphorylation in Alzheimer’s disease 
allows attempts to assemble filaments from intact pro- 
tein in different phosphorylation states. We show here 
that, using assembly conditions different from those suc- 
cessful for the repeat region, it is possible in vitro to 
produce twisted filaments resembling Alzheimer PHFs 
from full length recombinant tau protein, either in a 
non-phosphorylated state or after phosphorylation with 
brain extract. This observation raises the question of the 
All rights reserved. 
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role of the phosphorylation state of tau protein in the 
assembly of PHFs in vivo. 
2. Materials and methods 
2.1. Expression, purification and phosphorylation of tau protein 
Human tau protein with four repeats corresponding to the 441 amino 
acid isoform (clone htau40) was expressed in E. coli and purified by a 
modification of the published procedure [25]. Frozen E. coli pellets were 
sonicated in 10 ml/g extraction buffer (50 mM piperazine-NJ’-bis-2- 
ethanesulphonic acid (PIPES), pH 6.9, 1 mM dithiothreitol (DTT), 0.1 
mM EDTA, 0.1 mM phenylmethylsulphonyl fluoride (PMSF), 1 PM 
leupeptin, 1 FM pepstatin). After a 15 min spin (10,000 x g), the super- 
natant was brought o 0.5 M NaCl and incubated for 10 min in a boiling 
water bath. After another centrifugation the supernatant was dialysed 
twice at 4°C against buffer A (20 mM PIPES, pH 6.9, 50 mM NaCl, 
2 mM DTT, 1 mM EGTA, 1 mM MgSO,, 0.1 mM PMSF) and filtered 
through a 0.2 pm Arcodisc. The filtrate was applied to a Mono-S HR5/5 
column equilibrated in buffer A at a flow rate of 1 mumin and then 
eluted with a o-0.5 M gradient of NaCl in buffer A. One ml fractions 
were collected and aliquots run on SDS-PAGE. The peak tau fractions 
were dialvzed at 4°C aeainst 40 mM HEPES. pH 7.4. 1 mM DTT. 0.1 , I_ 
mM PMSF and stored frozen until use. 
The tau protein was phosphorylated by an extract from adult rat 
brain as described [l 11. Purification and phosphorylation were moni- 
tored by SDS-polyacrylamide gels and immuno-blotting with antibod- 
ies 134 (a general anti-tau antibody directed against he C-terminus) [7], 
AT8 [10,11,26] or T3P [5] (against epitopes phosphorylated at serine 
residues 202 or 396, respectively). Protein concentrations were esti- 
mated by Bradford assay (Biorad). In some cases the phosphorylated 
protein was purified by boiling to remove most of the brain extract 
proteins prior to concentration. After dialysis in 2 mM Tris-Cl, pH 7.5, 
tau samples for assembly trials were concentrated to approximately 10 
mg/ml by freeze drying and resuspension. 
2.2. Assembly offilaments and electron microscopy 
Filaments were grown by vapour diffusion in hanging drops in the 
standard way used for protein crystallization [27]. Trials were carried 
out with a range of buffers of different pH and ionic strength. Filaments 
were obtained at room temperature with the well buffer containing 0.5 
M Tris-Cl, 1.25 M potassium acetate, pH 6.9 or pH 7.4. 
Specimens were deposited on C-coated grids, which were sometimes 
glow-discharged prior to use, washed with a few drops of distilled water 
and stained with 1% LiPTA. Micrographs were recorded at a nominal 
magnification of x 45,000 on a Philips EM301 microscope. 
3. Results and discussion 
Tau protein corresponding to the 441 amino acid 
isoform from human brain was expressed and purified. 
It was phosphorylated using an extract from adult rat 
brain. The purification and phosphorylation were moni- 
tored by gel electrophoresis and immuno-blotting. The 
characteristic shift to lower mobility after phosphoryla- 
tion is shown by staining with the general tau antibody 
134 (Fig. 1). Similar gels stained with antibodies specific 
for phosphorylated serine residues 202 (antibody AT8) 
or 396 (antibody T3P) indicated that the incubation with 
brain extract produced a high level of phosphorylation 
at these sites (Fig. 1). Under the conditions used, approx- 
imately 8 mol of phosphate per mol of tau were incorpo- 
rated (data not shown). 
Assembly trials over a range of buffer conditions were 
made both with non-phosphorylated tau and with tau 
134 T3P 
Fig. 1. Immuno-blots of expressed human tau protein before and after 
phosphorylation. In each panel lane 1 represents the 441 amino acid 
isoform before phosphorylation, lane 2 after phosphorylation. Staining 
with the general tau antibody 134 shows a shift to lower mobility after 
phosphorylation. Phosphorylation specific antibodies T3P and AT8 
show no staining before phosphorylation but strong staining after- 
wards. 
phosphorylated by brain extract. Filaments were found 
for both forms of protein at neutral or slightly alkaline 
pH 6.9-7.4 in 0.5 M Tris, 1.25 M potassium acetate. 
These are different from the conditions used previously 
for producing filaments from the repeat region frag- 
ments, which involved acidic conditions in the range pH 
4.5-5. 
The majority species of filament produced under these 
conditions from non-phosphorylated tau is thin, with 
images from negatively stained specimens howing alter- 
nating regions of strong and weak stain exclusion, which 
give the images a dashed appearance (Fig. 2). The appar- 
ent axial period of these filaments is approximately 25 
nm and their width alternates between about 4.5 nm and 
9 nm. Their appearance is rather like very tiny PHFs and 
we propose to call them ‘dashed mini-filaments’. The 
arrangement of tau molecules in such structures is un- 
known but we are not suggesting that it is related to the 
arrangement of tau in PHFs. Amongst the dashed mini- 
filaments, examples of much more clearly twisted rib- 
bon-like filaments are found (Fig. 2). The images of these 
filaments alternate in width between about 4.5 nm and 
13 nm with an apparent period of 165 nm. Such filaments 
are reminiscent of Alzheimer PHFs, though the relative 
proportions of the features are different. However, their 
existence indicates that non-phosphorylated tau can be 
assembled into twisted filaments. 
The majority species assembled from phosphorylated 
tau under these conditions is also the dashed mini-fila- 
ment (Fig. 3a). Again amongst these are found twisted 
filaments but now with proportions much more like 
those of Alzheimer PHFs. The example in Fig. 3a alter- 
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Fig. 2. Filaments assembled in vitro from the non-phosphorylated 441 
amino acid isoform of human tau. The majority of filaments are of the 
dashed mini-filament ype (see text) but some larger twisted filaments 
are found (arrows). Bar = 100 nm. 
nates in width between about 7 nm and 18 nm with an 
apparent period of 83 nm. The example in Fig. 3b has 
a longer pitch but shows clearly a single stranded region 
at one end, indicating that these structures are ‘paired 
helical filaments’ consisting of two strands of subunits. 
Fig. 3d shows a filament with much longer pitch which 
resembles the unwound ribbons formed from Alzheimer 
PHFs by treatment with formic acid [28] and in particu- 
lar shows a region which clearly exhibits two pairs of 
stain excluding lines of density running parallel to the 
axis of the filament. Such an appearance is characteristic 
of Alzheimer PHFs and arises from the intrinsic arrange- 
ment of subunits within the PHF [29]. The twisted fila- 
ments formed from phosphorylated tau (Fig. 3) appear 
more similar to Alzheimer PHFs than do those made 
from non-phosphorylated tau (Fig. 2), in that their pro- 
portions are more like those of PHFs and that the nar- 
row cross-over region shows a greater stain excluding 
density. 
These results indicate that twisted filaments resem- 
bling Alzheimer PHFs can be assembled at physiological 
pH but high ionic strength from both phosphorylated 
and non-phosphorylated full-length tau. The Alzheimer- 
like filaments assembled from fragments corresponding 
to the repeat region were produced at much lower pH 
[23,24]. The majority species, the dashed mini-filament, 
produced from both states of the full-length protein ap- 
pears very different from PHFs. Its existence mphasizes 
137 
the range of filamentous structures formed by tau and 
mirrors the polymorphism found in the disease, where 
both PHFs and straight filaments are found [30]. The 
observation that both non-phosphorylated and phos- 
phorylated tau can be assembled into twisted filaments 
raises the question of the role of the hyper-phosphoryla- 
tion of tau in the pathology of Alzheimer’s disease. While 
the markedly reduced affinity of PHF-tau for microtu- 
bules that results from its hyper-phosphorylation [3 1,321 
probably affects the integrity of neuronal microtubules, 
it is not clear whether the phosphorylation of tau per se 
also promotes PHF assembly. The cluster of actual and 
potential phosphorylation sites just N-terminal of the 
repeat region overlaps with a strongly basic region of the 
protein. We have suggested that one result of phospho- 
rylation might be to neutralize this region partially, thus 
overcoming a charge repulsion that might normally in- 
hibit assembly of the non-phosphorylated protein [33]. 
The present results do not necessarily cast doubt on such 
a model, because the in vitro assembly conditions used 
Fig. 3. Filaments assembled in vitro from the 441 amino acid isoform 
of human tau phosphorylated by brain extract. (a) shows two dashed 
mini-filaments and a PHF-like twisted filament (arrow). (bd) Show 
other examples of twisted filaments with a range of pitches. In (b) the 
arrow indicates a region of ‘half-filament’. In (d) the arrow indicates 
a region of ribbon-like filament, in which two pairs of white stain- 
excluding tracks run parallel to the axis of the filament. Bar = 100 nm. 
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here, though at physiological pH, are otherwise far from 
physiological, particularly with respect to high protein 
concentration and high ionic strength. The abnormal 
hyper-phosphorylation of tau in the brain in Alzheimer’s 
disease may in some way lower the concentration neces- 
sary for assembly in vivo, such that, in the long time scale 
of the disease, hyper- phosphorylated tau assembles into 
PHFs whereas normal tau does not. Further experiments 
are in progress in an attempt to improve the efficiency 
of assembly and to investigate more closely the differ- 
ences that phosphorylation makes to assembly. 
Acknowledgements: We thank Dr. V.M.Y. Lee for the T3P antibody 
and Dr. E. Vanmechelen (Innogenetics) for the AT8 antibody. We 
thank C. Villa for help with photography. 
References 
[1] Goedert, M., Wischik, CM., Crowther, R.A., Walker, J.E. and 
Klug, A. (1988) Proc. Natl. Acad. Sci. USA 85, 40514055. 
[2] Wischik, C.M., Novak, M., Thogersen, H.C., Edwards, P.C., 
Runswick, M.J., Jakes, R., Walker, J.E., Milstein, C., Roth, M. 
and Klug, A. (1988) Proc. Natl. Acad. Sci. USA 85, 45064510. 
[3] Kondo, J., Honda, T., Mori, H., Hamada, Y., Miura, R., Oga- 
wara, M. and Ihara, Y. (1988) Neuron 1, 827-834. 
[4] Greenberg, SC. and Davies, P. (1990) Proc. Natl. Acad. Sci. USA 
87, 5827-5831. 
[5] Lee, V.M.-Y., Balin, B.J., Otvos, L. and Trojanowski, J.Q. (1991) 
Science 25 1, 675678. 
[6] Goedert, M., Spillantini, M.G., Potier, MC., Uhich, J. and 
Crowther, R.A. (1989) EMBO J. 8, 393-399. 
[7] Goedert, M., Spillantini, M.G., Jakes, R., Rutherford, D. and 
Crowther, R.A. (1989) Neuron 3, 519-526. 
[8] Ksiezak-Reding, H. and Yen, S.-H. (1991) Neuron 6, 717-728. 
[9] Goedert, M., Spillantini, M.G., Cairns, N.J. and Crowther, R.A. 
(1992) Neuron 8, 159168. 
[lo] Biemat, J., Mandelkow, E.-M., Schroter, C., Lichtenberg-Kraag, 
B., Steiner, B., Berling, B., Meyer, H., Mercken, M., Vander- 
meeren, A., Goedert, M. and Mandelkow, E. (1992) EMBO J. 11, 
1593-1597. 
[ll] Goedert, M., Jakes, R., Crowther, R.A. Six, J., Liibke, U., 
Vandermeeren, M., Cras, P., Trojanowski, J.Q. and Lee, V.M.-Y. 
(1993) Proc. Natl. Acad. Sci. USA 90, 50665070. 
[12] Hasegawa, M., Morishima-Kawashima, M., Takio, K., Suzuki, 
M., Titani, K. and Ihara, Y. (1992) J. Biol. Chem. 267, 17047- 
17054. 
[13] Drewes, G., Lichtenberg-Kraag, B., Doting, F., Mandelkow, E.- 
M., Biemat, J., Goris, J., Dome, M. and Mandelkow, E. (1992) 
EMBO J. 11, 2131-2138. 
[14] Goedert, M., Cohen, E.S., Jakes, R. and Cohen, P. (1992) FEBS 
Lett. 312, 95-99. 
[15] Hanger, D.P., Hughes, K., Woodgett, J.R., Brion, J.-P. and An- 
derton, B.H. (1992) Neurosci. Lett. 147, 58-62. 
[16] Mandelkow, E.-M., Drewes, G., Biemat, J., Gustke, N., Van Lint, 
J., Vandenheede, J.R. and Mandelkow, E. (1992) FEBS Lett. 314, 
315-321. 
[17] Vulliet, R., Halloran, S.M., Braun, R.K., Smith, A.J. and Lee, G. 
(1992) J. Biol. Chem. 267, 22570-22574. 
[18] Lee, G., Neve, R.L. and Kosik, K.S. (1989) Neuron 2,1615-1624. 
[19] Butner, K.A. and Kirschner, M.W. (1991) J. Cell Biol. 115, 717- 
730. 
[20] Biemat, J., Gustke, N., Drewes, G., Mandelkow, E.-M. and Man- 
delkow, E. (1993) Neuron 11, 153-163. 
[21] Wischik, C.M., Novak, M., Edwards, P.C., Klug, A., Tichelaar, 
W. and Crowther, R.A. (1988) Proc. Natl. Acad. Sci. USA 85, 
48844888. 
[22] Jakes, R., Novak, M., Davison, M. and Wischik, CM. (1991) 
EMBO J. 10, 2725-2729. 
[23] Wille, H., Drewes, G., Biemat, J., Mandelkow, E.-M. and Man- 
delkow, E. (1992) J. Cell Biol. 118, 573-584. 
[24] Crowther, R.A., Olesen, O.F., Jakes, R. and Goedert, M. (1992) 
FEBS Lett. 309, 199-202. 
[25] Goedert, M. and Jakes, R. (1990) EMBO J. 9, 42254230. 
[26] Mercken, M., Vandermeeren, M., Liibke, U., Six, J., Boons, J., 
Van de Voorde, A., Martin, J.J. and Gheuens, J. (1992) Acta 
Neuropathol. 84, 265-272. 
[27] Ducruix, A. and Giege, R. (1992) Crystallization of Nucleic Acids 
and Proteins ~ A Practical Approach, IRL Press, Oxford. 
[28] Crowther, R.A. (1991) B&hem. Biophys. Acta 1096, l-9. 
[29] Crowther, R.A. and Wischik, C.M. (1985) EMBO J. 4,3661-3665. 
[30] Crowther, R.A. (1991) Proc. Natl. Acad. Sci. USA 88,2288-2292. 
[31] Bramblett, G.T., Goedert, M., Jakes, R., Merrick, S.E., Trojanow- 
ski, J.Q. and Lee, V.M.-Y. (1993) Neuron 10, 1089-1099. 
[32] Yoshida, H. and Ihara, Y. (1993) J. Neurochem. 61, 1183-1186. 
[33] Goedert, M., Jakes, R., Spillantini, M.G. and Crowther, R.A. 
(1994) in: Microtubules (Hyams, J.S. and Lloyd, C. eds.) pp.l83- 
200, Wiley-Liss Inc., New York. 
